Literature DB >> 15832904

Bilateral oculosympathetic paresis associated with loss of nocturnal melatonin secretion in patients with spinal cord injury.

Jamie M Zeitzer1, Najib T Ayas, Allan D Wu, Charles A Czeisler, Robert Brown.   

Abstract

BACKGROUND: Lesions along the sympathetic pathway to the eye produce oculosympathetic paresis (OSP, Horner's syndrome). The oculosympathetic pathway descends from the hypothalamus through the cervical spinal cord and ascends to the superior cervical ganglion (SCG), which innervates sympathetic targets in the ipsilateral face and eye. This pathway appears to closely co-localize with a similar retino-pineal neural pathway from the hypothalamus through the cervical spinal cord and SCG to the pineal gland. As such, lesions along this shared pathway, such as occur in neurologically complete injury to the cervical spinal cord (tetraplegia), would be predicted to result in simultaneous OSP and loss of pineal melatonin production. Loss of melatonin production may contribute to the pervasive sleep disruption observed in patients with tetraplegia.
METHODS: We assessed the presence of OSP by photographic documentation of ptosis and pupillary dilation response to cocaine eye drops in 5 individuals with neurologically complete damage to their upper thoracic or lower cervical spinal cord. We correlated these results with an analysis of the pattern of melatonin production in these same individuals.
RESULTS: Bilateral OSP was present in individuals with cervical spinal cord injury; each also lacked significant production of melatonin. No evidence of OSP was observed in the 2 individuals with thoracic spinal cord injury below the level of the oculosympathetic pathway. Both had normal circadian rhythms of melatonin production, with timing and amplitude of the rhythm within normal parameters.
CONCLUSION: The presence of bilateral oculosympathetic paresis can be predictive of the complete loss of the nocturnal production of melatonin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832904     DOI: 10.1080/10790268.2005.11753798

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  8 in total

1.  Decreased sensitivity to phase-delaying effects of moderate intensity light in older subjects.

Authors:  Jeanne F Duffy; Jamie M Zeitzer; Charles A Czeisler
Journal:  Neurobiol Aging       Date:  2006-04-18       Impact factor: 4.673

2.  The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis.

Authors:  F Koc; S Kavuncu; T Kansu; G Acaroglu; E Firat
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

Review 3.  Horner's syndrome, Pseudo-Horner's syndrome, and simple anisocoria.

Authors:  Timothy J Martin
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

4.  Antiinflammatory activity of melatonin in central nervous system.

Authors:  Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

5.  Analysis method and experimental conditions affect computed circadian phase from melatonin data.

Authors:  Hadassa Klerman; Melissa A St Hilaire; Richard E Kronauer; Joshua J Gooley; Claude Gronfier; Joseph T Hull; Steven W Lockley; Nayantara Santhi; Wei Wang; Elizabeth B Klerman
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

6.  Neuropeptide Y in the adult and fetal human pineal gland.

Authors:  Morten Møller; Pansiri Phansuwan-Pujito; Corin Badiu
Journal:  Biomed Res Int       Date:  2014-03-17       Impact factor: 3.411

Review 7.  Melatonin for the treatment of spinal cord injury.

Authors:  Yan Zhang; Wen-Xiu Zhang; Yan-Jun Zhang; Ya-Dong Liu; Zong-Jian Liu; Qi-Chao Wu; Yun Guan; Xue-Ming Chen
Journal:  Neural Regen Res       Date:  2018-10       Impact factor: 5.135

8.  Horner's Syndrome as a Complication of Ultrasound-Guided Central Cannulation: A Case Report.

Authors:  Leonor Silva; Ana Filipa Junqueira; Rita Pato; Sílvia Farraposo; Ana Rita Cruz; Teresa Rocha
Journal:  Cureus       Date:  2022-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.